NGAM Advisors L.P. lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.8% during the second quarter, Holdings Channel reports. The institutional investor owned 101,797 shares of the medical equipment provider’s stock after selling 19,139 shares during the period. NGAM Advisors L.P.’s holdings in Hologic were worth $4,620,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in HOLX. Teachers Advisors LLC increased its position in shares of Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock valued at $25,819,000 after buying an additional 143,960 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its position in shares of Hologic by 3.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 240,769 shares of the medical equipment provider’s stock valued at $10,245,000 after buying an additional 8,289 shares in the last quarter. Gulf International Bank UK Ltd increased its position in shares of Hologic by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 74,164 shares of the medical equipment provider’s stock valued at $3,155,000 after buying an additional 1,100 shares in the last quarter. National Pension Service increased its position in shares of Hologic by 55,168.1% in the first quarter. National Pension Service now owns 244,285 shares of the medical equipment provider’s stock valued at $10,433,000 after buying an additional 243,843 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares in the last quarter. 94.46% of the stock is owned by hedge funds and other institutional investors.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at 39.03 on Tuesday. The stock’s 50 day moving average is $45.06 and its 200 day moving average is $42.98. The firm has a market cap of $10.95 billion, a PE ratio of 14.54 and a beta of 0.90. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the prior year, the firm posted $0.51 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/08/ngam-advisors-l-p-has-4-62-million-position-in-hologic-inc-nasdaqholx.html.

Several equities research analysts have weighed in on HOLX shares. Canaccord Genuity restated a “buy” rating and issued a $53.00 price objective on shares of Hologic in a research report on Tuesday, May 9th. Stifel Nicolaus raised their price objective on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, May 11th. BTIG Research restated a “buy” rating and issued a $47.00 price objective on shares of Hologic in a research report on Sunday, May 14th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Hologic presently has a consensus rating of “Buy” and a consensus target price of $48.64.

In other news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $43.99, for a total value of $393,182.62. Following the completion of the transaction, the director now owns 23,810 shares of the company’s stock, valued at $1,047,401.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. Insiders sold 70,464 shares of company stock valued at $3,078,921 in the last ninety days. 0.79% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.